Related Experiment Videos
Levetiracetam: preliminary efficacy in generalized seizures
Dorothée G A Kasteleijn-Nolst Trenité1, Edouard Hirsch
1Neurological Department, Medical Center Alkmaar, Netherlands. d.kasteleijn@mca.nl
Summary
Levetiracetam shows promise for treating generalized seizures, including absence and myoclonic types, based on animal models and small studies. Further randomized controlled trials are needed to confirm its efficacy in epilepsy patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Levetiracetam (LEV) is an established antiepileptic drug (AED) effective for partial seizures.
- Limited data exists on LEV's efficacy in generalized seizure disorders.
Purpose of the Study:
- To review existing evidence on levetiracetam's effectiveness in generalized seizures.
- To assess its potential therapeutic role in various generalized epilepsy syndromes.
Main Methods:
- Review of animal models of epilepsy, including audiogenic seizures and absence epilepsy.
- Analysis of small open-label studies and case reports in human patients with generalized seizures.
- Evaluation of levetiracetam's therapeutic index in preclinical models.
Main Results:
- Levetiracetam demonstrated efficacy in animal models of generalized seizures, including absence epilepsy.
- Preclinical studies indicate a favorable therapeutic index for levetiracetam compared to other AEDs.
- Small human studies and case reports suggest levetiracetam may reduce seizure frequency in generalized, myoclonic, postanoxic, and post-encephalitic seizures.
Conclusions:
- Levetiracetam shows potential as a treatment option for generalized seizures.
- Further randomized controlled studies are warranted to establish definitive efficacy in generalized epilepsy syndromes.